Greenland Mines (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. The full press release is available at https://ibn.fm/x2pHA.
This patent grant is significant because it strengthens Greenland Mines' intellectual property estate in a key jurisdiction, potentially providing a competitive advantage in the development of Klotho-based therapies. The Klotho gene has been associated with longevity and cognitive function, and its modulation could offer new treatment pathways for devastating neurodegenerative conditions that currently have limited therapeutic options. By securing patent protection in Canada, the company not only safeguards its technology but also positions itself to potentially access the Canadian market and collaborate with research institutions in the country.
The advancement of KLTO-101 and KLTO-202 into manufacturing stages underscores the company's progress toward clinical development. For KLTO-202, which targets ALS, GMP manufacturing readiness is a critical step before regulatory filings and clinical trials. ALS is a rapidly progressive neurodegenerative disease with few effective treatments, and any new therapeutic approach is closely watched by the medical community and investors alike. The patent coverage across multiple indications, including Alzheimer's and Parkinson's diseases, broadens the potential impact of the technology.
However, it is important to note that the company's biotech division is still in early stages, and the path from patent protection to approved therapies is long and uncertain. Greenland Mines also operates a mining division focused on rare earth elements in Greenland, which adds a layer of complexity to its business model. Investors should consider the risks outlined in the company's SEC filings, including those related to clinical development, regulatory approvals, and financing. The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML.
